enVVeno Medical Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NVNO research report →
Companywww.envveno.com
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh.
- CEO
- Robert A. Berman
- IPO
- 2018
- Employees
- 37
- HQ
- Irvine, CA, US
Price Chart
Valuation
- Market Cap
- $180.71K
- P/E
- -0.38
- P/S
- 0.00
- P/B
- 0.30
- EV/EBITDA
- 0.09
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -66.39%
- ROIC
- -82.16%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-19,472,000 · 10.76%
- EPS
- $-33.06 · 97.87%
- Op Income
- $-20,899,000
- FCF YoY
- 7.72%
Performance & Tape
- 52W High
- $196.70
- 52W Low
- $8.67
- 50D MA
- $10.94
- 200D MA
- $25.77
- Beta
- 1.08
- Avg Volume
- 13.87K
Get TickerSpark's AI analysis on NVNO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 12, 26 | Duhay Francis | sell | 140 |
| Dec 16, 25 | BERMAN ROBERT ANDREW | other | 200,000 |
| Dec 16, 25 | Alavi Hamed | other | 50,000 |
| Dec 16, 25 | Glickman Marc H. | other | 100,000 |
| Dec 11, 25 | Duhay Francis | other | 135,883 |
| Dec 11, 25 | Gray Robert | other | 135,883 |
| Dec 11, 25 | Jenusaitis Matthew | other | 135,883 |
| Dec 11, 25 | Shrivastava Sanjay | other | 135,883 |
| Dec 11, 25 | Duhay Francis | sell | 4,900 |
| Sep 15, 25 | Duhay Francis | sell | 4,900 |
Our NVNO Coverage
We haven't published any research on NVNO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NVNO Report →